NCT05567133 Risk Indicators of Sarcoidosis Evolution-Unified Protocol
| NCT ID | NCT05567133 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of California, San Francisco |
| Condition | Sarcoidosis, Pulmonary |
| Study Type | OBSERVATIONAL |
| Enrollment | 200 participants |
| Start Date | 2023-01-10 |
| Primary Completion | 2030-03-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 200 participants in total. It began in 2023-01-10 with a primary completion date of 2030-03-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this study is to develop prediction models that can prognosticate patients with sarcoidosis using clinical data and blood markers that can be obtained during a clinic visit.
Eligibility Criteria
Inclusion Criteria: 1. Adults with a diagnosis of sarcoidosis over the age of 18 2. Case definition: we will follow the 1999 statement on sarcoidosis published by the American Thoracic Society for diagnosis which includes tissue biopsy confirmation and exclusion of alternative diagnoses including beryllium sensitization/chronic beryllium disease, mycobacterial, viral, and/or fungal infection Exclusion Criteria: 1. Inability to tolerate study procedures as determined by the investigator 2. Pregnant or breastfeeding 3. Concurrent medical diagnoses that would influence the expression of biomarkers will be considered an exclusion criterion. This includes diseases such as common variable immunodeficiency, HIV infection, or autoimmune diseases 4. Concurrent interstitial lung diseases such as hypersensitivity pneumonitis or idiopathic pulmonary fibrosis 5. Hematocrit (Packed Cell Volume) \< 25%
Contact & Investigator
Laura Koth
PRINCIPAL INVESTIGATOR
University of California, San Francisco
Frequently Asked Questions
Who can join the NCT05567133 clinical trial?
This trial is open to participants of all sexes, aged 19 Years or older, studying Sarcoidosis, Pulmonary. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05567133 currently recruiting?
Yes, NCT05567133 is actively recruiting participants. Contact the research team at laura.koth@ucsf.edu for enrollment information.
Where is the NCT05567133 trial being conducted?
This trial is being conducted at Baltimore, United States, Dallas, United States.
Who is sponsoring the NCT05567133 clinical trial?
NCT05567133 is sponsored by University of California, San Francisco. The principal investigator is Laura Koth at University of California, San Francisco. The trial plans to enroll 200 participants.